No Detail Found!

Efficacy of Standardised Treatments Combined with Ubenimex in Patients with Malignant Tumors

Author(s)
Xin Hu Department of Oral and Maxillofacial Surgery, Xiangya Hospital, Central South University,China
Haofeng Xiong Department of Oral and Maxillofacial Surgery, Xiangya Hospital, Central South University, China
Shiying Huang Department of Oral and Maxillofacial Surgery, Xiangya Hospital, Central South University, China
Ting Mao Department of Oral and Maxillofacial Surgery, Xiangya Hospital, Central South University, China
Liudi Yang Department of Oral and Maxillofacial Surgery, Xiangya Hospital, Central South University, China
Tong Su Department of Oral and Maxillofacial Surgery, Xiangya Hospital, Central South University, China
Abstract
Ubenimex is widely used as an immunomodulator in the treatment of leukemia and non-small cell lung cancer to improve the anti-tumor treatment e ect. However, there has not been any multicenter randomised controlled trials to study its impact on the prognosis of cancer patients. The authors aimed to conduct a meta-analysis to initially study these issues. Pubmed, Cochrane Library and EMbase were searched. Randomised controlled trials of the e ects of ubenimex on the survival rate of malignant tumor patients were included in the meta-analysis. Survival rate ratio (OR) and 95% con dence interval (95% CI) between two groups were used to evaluate the e cacy of ubenimex. Fixed e ects models were used for meta-analysis. A total of 1,372 cases (684 in the ubenimex group and 688 in the control group) of ve studies were included. Between the ubenimex group and the control group, the 1-year OR was 1.40 (95% CI = 1.06 to 1.85), the 2-year OR was 1.43 (95% CI = 1.08 to 1.89) and the 3-year OR was 1.39 (95% CI = 1.07 to 1.81).Standardised treatments combined with ubenimex may improve the survival rate of patients with malignant tumors.
Publication Details
Page(s) 206-209
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 31, Issue: 2, Year: 2021

Request the full text from PASTIC

Keywords
Meta-analysis, Ubenimex, Malignant tumors, Randomised controlled trials
0

Citations

0

Downloads

89

Views